Provided is an organic light emitting device including a light emitting layer comprising a compound of Chemical Formula 1 and a first organic material layer comprising a compound of Chemical Formula 2:

##STR00001## wherein: Cy1 to Cy5 are each independently one selected from among a substituted or unsubstituted: aromatic hydrocarbon ring, aliphatic hydrocarbon ring, and aromatic hetero ring, or a ring in which two or more rings selected from the above group are fused, one or more of Cy1 to Cy5 are a ring of Chemical Formula 1-A:

##STR00002## one to three of a* to d* are a position fused to or linked to Chemical Formula 1;

##STR00003## L1 to L3 are each independently a direct bond or a substituted or unsubstituted: arylene or divalent heterocyclic group; and Ar1 and Ar2 are each independently a substituted or unsubstituted: aryl or heterocyclic group.

The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:

##STR00001##

wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently —CR.sub.2═ or —N═, R.sub.2 is, for example, a halogen atom, R.sub.1 is, for example, —S(═O).sub.2—NH—R.sub.8, R.sub.8 is, for example, a C1-6 alkyl group, R.sub.3 is, for example, a hydrogen atom, R.sub.5 is, for example, a halogen atom, R.sub.6 is, for example, a hydrogen atom, and R.sub.4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

A compound of formula (1)

##STR00001##

wherein X.sub.1 is CR.sub.1 or a nitrogen atom, X.sub.2 is CR.sub.2 or a nitrogen atom, X.sub.3 is CR.sub.3 or a nitrogen atom, X.sub.4 is CR.sub.4 or a nitrogen atom, X.sub.5 is CR.sub.5 or a nitrogen atom, X.sub.6 is CR.sub.6 or a nitrogen atom, X.sub.7 is CR.sub.7, a nitrogen atom, or a carbon atom single-bonded to X.sub.8, X.sub.8 is CR.sub.8, a nitrogen atom, or a carbon atom single-bonded to X.sub.7, X.sub.9 is CR.sub.9 or a nitrogen atom, X.sub.10 is CR.sub.10 or a nitrogen atom, X.sub.11 is CR.sub.11 or a nitrogen atom, X.sub.12 is CR.sub.12 or a nitrogen atom, and Q is CR.sub.Q or a nitrogen atom, and Y is NR.sub.Y1, an oxygen atom, a sulfur atom, C(R.sub.Y2)(R.sub.Y3) or Si(R.sub.Y4)(R.sub.Y5), each R being a hydrogen atom or a substituent.

Disclosed are a heterocyclic compound represented by Formula 1-1 or 1-2,

##STR00001## wherein, in Formulae 1-1 and 1-2, X.sub.1, CY.sub.1 to CY.sub.3, R.sub.1 to R.sub.3, and a1 to a3, are the same as described in the specification. Also disclosed is an organic light-emitting device including the same.

An organic electroluminescence device of an embodiment includes a first electrode, a second electrode and a plurality of organic layers disposed between the first electrode and the second electrode, in which at least one of the organic layers includes a polycyclic compound including a plurality of electron donors and an electron acceptor connecting the electron donors, at least one of the electron donors is a condensed ring including a borepine core, and the electron acceptor includes a phenyl group including, as a substituent, at least one cyano group or a heterocycle including at least one nitrogen atom, or a heteroaryl group including an oxygen atom or a sulfur atom for forming a ring, thereby achieving improved emission efficiency.

Electrolytes and electrolyte additives for energy storage devices comprising functional thiophene compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, an electrolyte, and at least one electrolyte additive selected from a thiophene compound.

A compound having Nrf2-activating action is provided. The compound is represented by formula (I), a salt of the compound, or a solvate of the compound or salt:

##STR00001##

wherein R.sup.1a and R.sup.1b are identical or different and represent a hydrogen atom, an alkyl group, or a halogen atom; R.sup.2 represents an optionally substituted group derived from a heterocycle, and the heterocycle represents thiophene, furan, pyrrole, thiazole, or a fused ring including any of these heterocycles; R.sup.4 and R.sup.5 are identical or different and represent a hydrogen atom or an optionally substituted alkyl group, or R.sup.4 and R.sup.5 bind with each other to form —NH—CH—N—; R.sup.6 represents an optionally substituted alkyl group; A.sup.1, A.sup.2, A.sup.3, and A.sup.4 are identical or different and represent CH or N wherein the number of N is 1 or less; and Z represents a hydrogen atom or a halogen atom.

An organic borane complex contains, as a component, triarylborane having an enhanced bonding between a boron atom and a carbon atom on an aryl group. The organic borane complex contains, as a component, triarylborane having a structure represented by the following general formula (1), wherein X1 and X2 each independently represent an oxygen atom or a sulfur atom; X3 and X4 each independently represent a hydrogen atom or a substituent, or X3 and X4 are linked together to be a single atom; R1 to R3 each independently represent a hydrogen atom or a substituent; and p, q and r each independently represent an integer of 1 to 3. Also disclosed are a composition containing organic borane, and an organic electroluminescent element.

Provided organic light emitting device (OLED) comprising compounds having Formula I:

##STR00001##

wherein rings A, B, C, D, E, and F are each independently a single or fused ring system, consisting of one or more 5-membered or 6-membered carbocyclic or heterocyclic rings; L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5, and L.sup.6 are each independently optionally present or is selected from the group consisting of O, S, Se, BR, BRR′, NR, C═R, CRR′, SiRR′, P(O)R, and GeRR′; a, b, c, d, e and f are each 0 for not present or 1 for present; each of R, R′, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 is independently a hydrogen or a substituent; and any two of adjacent R, R′, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 can be joined or fused to form a ring. The compound is an ETL.

The present invention concerns a compound of formula (I):

##STR00001##

or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.